64x Bio

Executive Summary

64x Bio is a San Francisco-based private company founded in 2020, operating at the intersection of cell therapy, gene therapy, and synthetic biology. The company has developed VectorSelect™, an end-to-end platform designed to enable next-generation biologics by revolutionizing cell line development and biologic manufacturing. VectorSelect™ offers scalable therapeutic systems for gene therapies and bioengineering, aiming to overcome key limitations in the production of complex biologics. While specific financials, clinical pipelines, and funding details are not publicly disclosed, the platform's focus on scalability and efficiency positions it as a potential enabler in the biologics manufacturing space. The company's early-stage status and lack of published milestones suggest it is still in the pre-clinical or early development phase, with a need for validation through partnerships or funding rounds.

Upcoming Catalysts (preview)

• Q4 2025Series A Funding Announcement60% success
• Q2 2026First Major Partnership or Licensing Deal50% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data40% success